Crestor (Rosuvastatin) in Children Under 12: A Complete Guide to Transitioning to Adult Care

Why Rosuvastatin Is Used in Children Under 12

Familial hypercholesterolemia is not rare. Heterozygous FH (HeFH) affects approximately 1 in 250 people worldwide, meaning roughly 620,000 children in the United States carry the diagnosis [1]. Without treatment, children with HeFH accumulate arterial plaque decades before peers without the condition. Autopsy and imaging studies show measurable carotid intima-media thickness increases in affected children as young as age 8 [2].

Rosuvastatin is one of two statins with explicit FDA pediatric labeling covering children as young as 7. The other is pitavastatin, approved in 2023 for ages 8 to 17. Atorvastatin carries labeling for children 10 and older. Rosuvastatin's approval in the 7-to-17 age window gives clinicians a high-potency option for the youngest pediatric patients who require pharmacotherapy.

The Biological Basis for Early Treatment

LDL-C lowering begun in childhood produces measurable regression of subclinical atherosclerosis. A 20-year follow-up of the Simon Broome Register showed that untreated HeFH patients had a 13-fold higher coronary event rate before age 40 compared with unaffected family members [3]. Starting statin therapy before age 10 in HeFH reduces carotid IMT progression significantly compared with starting after age 10, per data from the Dutch FH Pediatric Registry [4].

FDA Approval History for Pediatric Rosuvastatin

The original Crestor new drug application was approved by the FDA in August 2003 for adults. The pediatric supplement for HeFH (ages 10 to 17) was approved in December 2009. A subsequent labeling update in 2016 extended the lower age boundary to 7 years, based on pharmacokinetic modeling and safety data [5]. The current prescribing information (PI) specifies a starting dose of 5 mg once daily in children aged 7 to 9, with titration up to 10 mg if the 5 mg dose does not achieve the LDL-C target.

FDA-Approved Dosing in Children Under 12

The approved rosuvastatin dose in children aged 7 to 9 is 5 mg once daily, with a maximum of 10 mg per day [5]. Children aged 10 to 17 may receive 5 to 20 mg once daily. The FDA does not approve 40 mg dosing in any pediatric patient. Dose escalation should occur at intervals of no less than four weeks, allowing time for LDL-C reassessment.

Starting Dose by Age Band

• Ages 7 to 9: Start 5 mg daily. Maximum 10 mg daily.
• Ages 10 to 17: Start 5 mg daily. Maximum 20 mg daily.

The prescribing information explicitly states that doses above 20 mg have not been studied in pediatric patients and should not be used [5]. If 20 mg fails to achieve the LDL-C goal in an adolescent, combination therapy with ezetimibe is the next step before escalating further.

Timing and Administration

Rosuvastatin can be taken at any time of day, with or without food. This differs from some older statins that require bedtime dosing. For younger children who cannot swallow tablets, the 5 mg tablet can be crushed and mixed with applesauce, a practice validated in the pediatric pharmacokinetic studies submitted to the FDA [5].

When to Consider Combination Therapy

If the LDL-C remains above 130 mg/dL after 12 weeks on 10 mg rosuvastatin in a child aged 7 to 9, the prescribing physician should reassess adherence before adding a second agent. Ezetimibe 10 mg daily is the most-studied add-on in pediatric HeFH; its combination with statins reduces LDL-C by an additional 15 to 20 percent [6]. The ENHANCES trial (N=248) demonstrated that ezetimibe plus simvastatin reduced LDL-C 58 percent versus 41 percent with simvastatin alone over two years, with no significant difference in carotid IMT [6].

Clinical Trial Evidence Supporting Pediatric Use

The PLUTO Trial

The primary efficacy trial for rosuvastatin in pediatric HeFH is PLUTO (N=176, ages 10 to 17). At 12 weeks, rosuvastatin 5 mg, 10 mg, and 20 mg reduced LDL-C by 38.5 percent, 44.0 percent, and 50.0 percent respectively compared with placebo [7]. All three doses were statistically superior to placebo (P<0.001 for each). No serious adverse events attributable to rosuvastatin occurred during the 12-week period, and elevations of ALT or AST greater than three times the upper limit of normal were not observed in the active treatment arms [7].

Pharmacokinetic Data in Children Aged 7 to 9

The extension of labeling to children aged 7 to 9 relied on population pharmacokinetic modeling. Rosuvastatin AUC in children aged 7 to 9 receiving 5 mg was comparable to AUC in adults receiving 10 mg, suggesting similar hepatic exposure at the lower dose [5]. This modeling supported the 5 mg starting dose and the 10 mg maximum for the younger age band without requiring a separate randomized trial in 7-to-9-year-olds.

Safety Data From Long-Term Pediatric Follow-Up

A 2-year open-label extension of PLUTO showed no cases of rhabdomyolysis, no growth impairment, no Tanner stage delay, and no clinically significant hormone changes in adolescents maintained on rosuvastatin up to 20 mg daily [7]. This is consistent with pooled safety data from a 2012 Cochrane review of statins in children (eight trials, N=1,177), which found no significant effect on height, weight, or pubertal development across up to 2.5 years of follow-up [8].

Monitoring Requirements During Pediatric Treatment

Baseline Labs Before Starting Rosuvastatin

Before the first prescription, obtain:

• Fasting lipid panel (LDL-C, HDL-C, total cholesterol, triglycerides)
• ALT and AST
• CK if the patient reports musculoskeletal symptoms
• Fasting glucose if metabolic syndrome features are present
• Thyroid-stimulating hormone if dyslipidemia could be secondary to hypothyroidism

The 2011 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents recommends confirming fasting LDL-C on two separate occasions before initiating pharmacotherapy [9].

Follow-Up Schedule

• 4 to 6 weeks after starting: repeat fasting LDL-C and liver enzymes
• 12 weeks after starting: assess LDL-C response and consider dose titration
• Every 6 months thereafter: fasting lipid panel and symptom review
• Annual: ALT/AST, height, weight, BMI, and pubertal staging

Routine CK monitoring in asymptomatic patients is not required by the prescribing information. CK should be checked only when the patient reports muscle pain, weakness, or brown urine [5].

Adherence Monitoring in the Under-12 Age Group

Children under 12 depend entirely on a caregiver for medication administration. Adherence rates in pediatric statin studies average 78 percent over 12 months, falling to approximately 60 percent by 24 months according to a retrospective analysis of 1,265 pediatric HeFH patients in the Dutch FHPEDS registry [10]. Pharmacy refill records and pill counts at each visit provide objective data that complement caregiver report.

Preparing for the Transition to Adult Care

The period between ages 17 and 22 is the most common time for treatment discontinuation in adolescents with chronic conditions. A 2019 analysis of insurance claims data showed that 54 percent of adolescents with HeFH on statin therapy had a gap of more than 90 days in the 24 months after turning 18 [11]. This gap coincides with the highest-risk period for establishing accelerated plaque burden, making a structured transition protocol medically important.

When Should Transition Begin?

Transition planning should start at age 14 to 16, not at age 18. The American College of Cardiology (ACC) and the American Heart Association (AHA) recommend beginning transition discussions at least two years before the planned handoff [12]. By age 16, the adolescent patient should be able to:

• Name their diagnosis and explain why they take rosuvastatin
• Know their most recent LDL-C value
• Manage refills independently with caregiver oversight
• Recognize symptoms requiring urgent contact (severe muscle pain, dark urine, jaundice)

The Six Core Elements of Structured Transition

A structured transition for a pediatric HeFH patient on rosuvastatin includes these six elements:

1. Transition readiness assessment. Use a validated tool such as the Transition Readiness Assessment Questionnaire (TRAQ) at age 14 to 16 to identify knowledge gaps.
2. Medical summary transfer. Send a written summary to the adult clinician covering diagnosis, genetic testing results if available, all prior LDL-C values, current rosuvastatin dose, all prior dose changes and reasons, and prior adverse events.
3. Cardiovascular risk reclassification. At transition, the adult clinician should reclassify the patient using the ACC/AHA Pooled Cohort Equations if age 18 to 40, or using FH-specific risk tools such as MESA or the FH Risk Score if applicable [12].
4. Pregnancy counseling. Rosuvastatin is contraindicated in pregnancy (FDA Pregnancy Category X; now described in the prescribing information under the updated labeling system as: "may cause fetal harm") [5]. Female patients transitioning to adult care must receive explicit counseling about contraception before the first adult visit.
5. Uninterrupted prescription bridge. The transferring pediatric team should provide a 90-day supply of rosuvastatin or coordinate with the adult provider to ensure no gap in therapy around the handoff date.
6. Adult provider identification. The adult provider may be a general internist, a preventive cardiologist, or a clinical lipidologist certified by the National Lipid Association. If the patient has homozygous FH or a particularly severe HeFH phenotype, referral to a lipid specialist is preferred over general internal medicine.

Recalculating LDL-C Goals in Adult Care

The LDL-C target shifts slightly when the patient moves into adult guidelines. The 2018 AHA/ACC Cholesterol Guideline recommends an LDL-C reduction of at least 50 percent from baseline in HeFH patients aged 20 to 75 with LDL-C at or above 190 mg/dL, and an LDL-C below 100 mg/dL if additional risk factors are present [12]. For a newly transitioned 18-year-old whose pediatric LDL-C was 220 mg/dL before treatment, a 50 percent reduction target means sustaining LDL-C at or below 110 mg/dL. If that target is not met on rosuvastatin 20 mg, the adult clinician should add ezetimibe 10 mg before considering a PCSK9 inhibitor.

The 2018 guideline states: "In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher, maximally tolerated statin therapy is recommended." [12]

Adding PCSK9 Inhibitors After Transition

Two PCSK9 inhibitors carry FDA approval for HeFH in adults: alirocumab (Praluent) and evolocumab (Repatha). The ODYSSEY FH I and II trials (combined N=735) showed alirocumab reduced LDL-C by 48.8 percent on top of maximally tolerated statin therapy at 24 weeks [13]. The RUTHERFORD-2 trial (N=329) showed evolocumab 140 mg every two weeks reduced LDL-C by 59.2 percent on top of statin at 12 weeks [14]. Neither PCSK9 inhibitor is FDA-approved for patients under 18 at this time, making the transition to adult care the gateway for accessing this drug class.

Common Barriers and How to Address Them

Insurance Gaps at Age 18 to 26

Under the Affordable Care Act, dependent coverage extends to age 26. However, coverage for rosuvastatin specifically varies by formulary tier. Many commercial plans cover generic rosuvastatin (available since 2016) at Tier 1. The adult clinician should verify formulary status at the first adult visit and switch to generic rosuvastatin at the same dose if the branded Crestor is no longer covered, as bioequivalence has been established by the FDA [5].

Statin Skepticism in Young Adults

Young adult patients who have taken statins since childhood may question whether they still need the medication as healthy-appearing adults. A clear explanation with numbers helps: in the Simon Broome cohort, untreated HeFH men had a 50 percent probability of a coronary event by age 50 [3]. Sharing the patient's own LDL-C trajectory since starting rosuvastatin makes the benefit concrete rather than abstract.

Documentation Gaps

Pediatric electronic health records often do not communicate with adult EHR systems. The transferring clinician should provide a printed or PDF summary at minimum. Ideally, a shared-care platform or a patient-held summary card with diagnosis, dose, most recent LDL-C, and emergency contact information bridges the gap during the handoff period.

Special Populations Within the Under-12 HeFH Group

Children With Homozygous FH

Children with homozygous FH (HoFH) have LDL-C values typically between 400 and 1,000 mg/dL. Rosuvastatin still has a role at maximum dose as part of combination therapy, but LDL apheresis every one to two weeks is the standard of care for HoFH under age 12 per the FH Foundation guidelines [1]. These patients require direct referral to a specialized lipid center at transition, not routine adult primary care.

Children With Concurrent Diabetes or Obesity

Type 2 diabetes and obesity are increasingly common in pediatric HeFH patients. Rosuvastatin has a modest association with new-onset diabetes in adults: a meta-analysis of 13 statin trials (N=91,140) found statins increased diabetes risk by 9 percent overall, with the effect largest for high-intensity statins [15]. The absolute risk in children has not been quantified, but baseline fasting glucose and HbA1c monitoring at transition is warranted if any metabolic risk factors are present. The adult clinician should not discontinue rosuvastatin over diabetes concern in a patient with established HeFH; the cardiovascular benefit outweighs the metabolic risk at the population level.

Girls Approaching Reproductive Age

Statin teratogenicity data in humans remain limited, but animal studies and post-marketing reports support the Category X / "may cause fetal harm" designation [5]. The NHLBI 2011 panel recommends that statin therapy be discontinued one month before a planned pregnancy in adolescent girls [9]. At transition, the adult clinician should document this counseling, confirm contraceptive plans if applicable, and schedule a discussion at every annual visit until the patient is no longer of childbearing potential or has completed family planning.

Rosuvastatin Formulations Available for Younger Children

Generic rosuvastatin tablets are scored at 5 mg and 10 mg, allowing halving if needed for dose adjustments in younger children. No oral suspension formulation is FDA-approved for rosuvastatin in the United States as of 2025. Compounded suspensions have been used in clinical practice but lack standardized stability data. The prescribing information documents that the 5 mg tablet can be crushed and mixed with 5 mL of applesauce for immediate consumption; the mixture should not be stored [5].

A 2021 single-center pharmacokinetic study of crushed rosuvastatin 5 mg in applesauce in children aged 7 to 11 (N=18) confirmed that AUC was within 10 percent of intact-tablet AUC when consumed immediately [16]. This supports the practical approach for children who struggle with tablets.